Original Articles Open access

Analysis of the risk factors of hepatitis on the rate of recovery in pulmonary tuberculosis patients

Authors

Published
26 August 2025
Section
Original Articles
DOI
10.4081/itjm.2025.2064

Abstract

Tuberculosis (TB) remains a major public health challenge, particularly in developing countries. Although anti-TB drugs are effective, their use is often associated with drug-induced hepatitis (DIH), which can impact treatment outcomes. Understanding the relationship between DIH risk factors and TB cure rates is critical for improving therapeutic success. This study aims to analyze the risk factors associated with DIH and assess their impact on the cure rate of pulmonary TB patients. A retrospective analytical observational study was conducted at Labuang Baji Hospital and Dr. Wahidin Sudirohusodo Hospital between January and March 2025. Data were collected from pulmonary TB patients who developed DIH between June 2023 and June 2024. A total of 90 subjects were included through total sampling. Demographic, clinical, and treatment variables were analyzed using univariate and bivariate methods with SPSS. Ethical approval was obtained prior to the study initiation. Among the 90 subjects, the mean age was 43.92 years, with 63.3% under 50 years old and 64.4% male. Low body mass index (<18.5 kg/m2) was prevalent in 60% of cases. Comorbidities included diabetes mellitus (21.1%), hypertension (21.1%), and HIV (16.7%). Most TB diagnoses were confirmed bacteriologically (78.9%). DIH occurred on average 8 days after treatment initiation, and 91.1% experienced it within 14 days. Extensive lung lesions were present in 37.8% of patients, and 60% were on a three-drug regimen. A cure was achieved in 80% of subjects, while 20% did not recover. Despite the occurrence of DIH, most TB patients recovered. Early identification of risk factors is important to prevent complications and improve outcomes.

Keywords

References

  1. Sedighzadeh SS, Khoshbin AP, Razi S, et al. A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Transl Lung Cancer Res 2021;10:1889-916. DOI: https://doi.org/10.21037/tlcr-20-1241
  2. Soni H, Kumar-M P, Mishra S, et al. Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta-analysis. Expert Rev Anti Infect Ther 2020;18:171-9. DOI: https://doi.org/10.1080/14787210.2020.1714436
  3. Verma S, Kaplowitz N. Hepatotoxicity of antitubercular drugs. In: Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. Cambridge, MA, USA: Academic Press; 2013. DOI: https://doi.org/10.1016/B978-0-12-387817-5.00027-3
  4. Faiz SN, Haque M. Antitubercular drug-induced hepatotoxicity: a comprehensive review. J Army Medical College Chattogram 2020;3:33-7.
  5. Soedarsono S, Riadi ARW. Tuberculosis drug-induced liver injury. J Respir 2020;6:49-54. DOI: https://doi.org/10.20473/jr.v6-I.2.2020.49-54
  6. Sun Q, Zhang Q, Gu J, Sun W. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf 2016;16:228. DOI: https://doi.org/10.1002/pds.3988
  7. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3:37-49. DOI: https://doi.org/10.1016/j.jceh.2012.12.001
  8. Wesnawa MADP, Kusmiati T. Drug-induced hepatitis in pulmonary tuberculosis with multisite extrapulmonary tuberculosis. J Respir 2020;5:34-40. DOI: https://doi.org/10.20473/jr.v5-I.2.2019.34-40
  9. Perhimpunan Dokter Paru Indonesia (PDPI). Tuberculosis: diagnosis and management. Indonesian Society of Respirology. 2011. doi:10.15562/ism.v13i3.1554 DOI: https://doi.org/10.15562/ism.v13i3.1554
  10. Khiewkhern S, Ruetrakul J, Thongkum W, Areeruk N. Factors enhancing drug-induced hepatotoxicity among Thai patients with TB. J Clin Diagn Res 2020;14:OC01-4. DOI: https://doi.org/10.7860/JCDR/2020/44816.14008
  11. Anastasia AS, Somia I, Arisanti NLE, et al. Clinical characteristics, serum albumin and eosinophil levels as risk factors for drug-induced hepatitis in tuberculosis patients receiving fixed-dose combination anti-tuberculosis drug. Int J Adv Med 2022;9:399-404. DOI: https://doi.org/10.18203/2349-3933.ijam20220776
  12. Dhania O. Evaluation of risk factors and changes in liver enzymes among the patients with antituberculosis drug-induced hepatitis: A teaching hospital based study. Asian J Med Res 2019;8:1-4. DOI: https://doi.org/10.21276/ajmr.2019.8.2.PM1
  13. Gupta V, Guleria T, Kumar S, et al. Anti-tuberculosis drug-induced hepatotoxicity: a study from the Himalayan region. Int J Res Med Sci 2022;10:713-6. DOI: https://doi.org/10.18203/2320-6012.ijrms20220524
  14. Freire ID, Fielding KL, Moore DAJ. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment? PLoS One 2023;18:e0286306. DOI: https://doi.org/10.1371/journal.pone.0286306
  15. Song J, Yoon S-Y, Park T, et al. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case-control study. Respir Res 2019;20:283. DOI: https://doi.org/10.1186/s12931-019-1256-y
  16. Anitha NA, Dasari R, Cherlopalli S, Sriram S. Study of antitubercular drugs on liver function tests in newly diagnosed tuberculosis. Nat J Physiol Pharm Pharmacol 2024;14:552-6. DOI: https://doi.org/10.5455/njppp.2023.13.07378202319082023
  17. Lin H-S, Lin M, Chi CC, et al. Nutrition assessment and adverse outcomes in hospitalized patients with tuberculosis. J Clin Med 2021;10:2702. DOI: https://doi.org/10.3390/jcm10122702
  18. Cavaco M, Alcobia C, Oliveiros B, et al. Clinical and genetic risk factors for drug-induced liver injury associated with anti-tuberculosis treatment—a study from patients of Portuguese health centers. J Pers Med 2022;12:790. DOI: https://doi.org/10.3390/jpm12050790
  19. Naidoo K, Hassan-Moosa R, Mlotshwa P, et al. High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the Starting Antiretroviral Therapy at Three Points in TB Trial. Clin Infect Dis 2020;70:2675-82. DOI: https://doi.org/10.1093/cid/ciz732
  20. Molla Y, Wubetu M, Alamirew BD. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepatic Med 2021;13:1-8. DOI: https://doi.org/10.2147/HMER.S290542
  21. Ali N, Gupta N, Saravu K. Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy: an experience from a tertiary care center in South India. Drug Discov Ther 2020;14:135-8. DOI: https://doi.org/10.5582/ddt.2020.03029
  22. Gezahegn LK, Argaw E, Assefa B, et al. Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study. PLoS One 2020;15:e0241346. DOI: https://doi.org/10.1371/journal.pone.0241346
  23. Ji S-Y, Lu B, Pan X. A nomogram model to predict the risk of drug-induced liver injury in patients receiving anti-tuberculosis treatment. Front Pharmacol 2023;14:1153815. DOI: https://doi.org/10.3389/fphar.2023.1153815
  24. Chidambaram V, Tun NL, Majella MG, et al. Male sex is associated with worse microbiological and clinical outcomes following tuberculosis treatment: a retrospective cohort study, a systematic review of the literature, and meta-analysis. Clin Infect Dis 2021;73:1580-8. DOI: https://doi.org/10.1093/cid/ciab527
  25. Barathi A, Krishnamoorthy Y, Sinha P, et al. Effect of treatment adherence on the association between sex and unfavourable treatment outcomes among tuberculosis patients in Puducherry, India: a mediation analysis. J Public Health 2023;45:304-11. DOI: https://doi.org/10.1093/pubmed/fdac062
  26. Danarastri S, Perry K, Hastomo YE, et al. Gender differences in health-seeking behaviour, diagnosis and treatment for TB. Int J Tuberc Lung Dis 2022;26:568-70. DOI: https://doi.org/10.5588/ijtld.21.0735
  27. Baluku J, Mukasa D, Bongomin F, et al. Gender differences among patients with drug-resistant tuberculosis and HIV co-infection in Uganda: a countrywide retrospective cohort study. BMC Infect Dis 2021;21:1093. DOI: https://doi.org/10.1186/s12879-021-06801-5
  28. Nadarajah K, Khan A, Ali I, et al. Gender differences and treatment outcome among drug-induced hepatotoxicity tuberculosis patients. Open Med J 2019;6:6-26. DOI: https://doi.org/10.2174/1874220301906010026

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.